vildagliptin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Vildagliptin, sold under the brand name Galvus and others, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.   Wikipedia

Chemistry

  • SMILES: OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N
  • InChIKey: SYOKIDBDQMKNDQ-XWTIBIIYSA-N
  • Mol. Mass: 303.41
  • ALogP: 1.17
  • ChEMBL Molecule:
    vildagliptin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.6270
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine | (2s)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile | equa | galvus | haaa-2-cyanopyrrolidine | jalra | laf237 | laf 237 | laf-237 | nvp-laf237 | nvp-laf-237 | vidagliptin | vildagliptin | vildagliptin hcl | vildagliptin hydrochloride | vildagliptin / metformin hydrochloride | xiliarx

Organizations (100)

Research & Development (100)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (37)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Aged (Phase 4)

Anesthesia (Phase 2/Phase 3)

Bone Diseases, Metabolic (Phase 4)

Cognitive Dysfunction (Phase 4)

Coronary Artery Disease (Phase 4)

Depressive Disorder, Major (Phase 1/Phase 2)

Diabetes Mellitus ()

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Diagnostic Self Evaluation (Phase 1)

Dyslipidemias (Phase 2)

Endothelial Cells (Phase 4)

Exercise (Phase 4)

Fasting (Phase 1)

Foot Ulcer (Phase 4)

Glucose Intolerance (Phase 2)

Healthy Volunteers (Phase 3)

Heart Failure (Phase 4)

Hypertension (Phase 4)

Hypoglycemia (Phase 4)

Hypoglycemic Agents (Phase 4)

Inflammation (Phase 4)

Insulin Resistance (Phase 3)

Kidney Failure, Chronic (Phase 1/Phase 2)

Kidney Transplantation (Phase 3)

Menopause (Phase 4)

Metabolic Syndrome (Phase 4)

Myocardial Ischemia (Phase 4)

Obesity (Phase 4)

Osteoporosis (Phase 4)

Oxidative Stress (Phase 4)

Polycystic Ovary Syndrome (Phase 2/Phase 3)

Prediabetic State (Phase 3)

Proteinuria (Phase 4)

Renal Insufficiency (Phase 4)

Schizophrenia (Phase 2)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 172
  • # of Trial Organizations: 100

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue